Ris-Rez positive early data in lung cancer

GSK’s Ris-Rez shows 61% response in phase Ib lung cancer trial, but risks remain.

What the company is saying

GSK plc is highlighting the first global phase Ib data for risvutatug rezetecan (Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate, in relapsed extensive-stage small cell lung cancer. The company frames the 61% objective response rate at the 8 mg/kg dose as a major advance, emphasizing manageable safety and the selection of this dose for ongoing global phase III trials. GSK references positive pivotal data from China and regulatory designations in the US, EU, and Japan to reinforce the credibility and momentum of the program. Hesham Abdullah, Senior Vice President and Global Head of Oncology R&D, positions these results as supporting accelerated development for a population with urgent unmet need. The announcement stresses the breadth of the EMBOLD clinical program, with over 1,000 patients dosed and multiple phase III trials underway or planned. The tone is confident and forward-looking, but the company acknowledges that longer follow-up is needed to confirm durability of response.

What the data suggests

The disclosed phase Ib data show a 61% confirmed objective response rate (ORR) at the 8 mg/kg dose (11 of 18 evaluable patients) and 32% at the 6 mg/kg dose (7 of 22 evaluable patients) in relapsed ES-SCLC. Grade 3 or higher treatment-related adverse events occurred in 42% of patients at 8 mg/kg and 15% at 6 mg/kg, with haematological events most common. The overall rate of interstitial lung disease was 2% (1 out of 50 patients), and the single case was moderate (grade 2). The trial population was heavily pretreated, with a median of two prior therapies, and included patients with prior topoisomerase-1 inhibitor or tarlatamab exposure and brain or liver metastases. The analysis covers 50 patients with a median follow-up of 100.5 days, and enrollment is ongoing. In China, Ris-Rez reduced risk of death by 54% versus topotecan in a pivotal trial. More than 1,000 patients have received Ris-Rez in GSK’s EMBOLD program, which includes multiple phase III trials. While efficacy and safety signals are promising, the data are early, and durability of response is not yet established.

Analysis

The announcement presents positive phase Ib clinical data for Ris-Rez, with a confirmed ORR of 61% at the higher dose and a manageable safety profile, supported by specific numerical disclosures. However, the majority of the narrative is forward-looking, emphasizing accelerated development, ongoing and planned phase III trials, and broad regulatory ambitions. No financial metrics (revenue, profit, R&D spend) are disclosed, and the acquisition of global rights signals significant capital outlay with no immediate earnings impact. The benefits (regulatory approval, commercialisation) are long-term, as pivotal phase III data and durability of response are still pending. Phrases like 'support accelerated development' and 'ambition to develop it across more than 40 indications by 2040' inflate the signal beyond the realised phase Ib results. The data supports further development but does not yet translate into commercial or profitability outcomes.

Risk flags

• ●Durability of response is unproven, as the median follow-up is only 100.5 days and longer observation is needed to confirm sustained benefit. Short-term responses in small cell lung cancer often do not translate into durable survival gains.
• ●Safety risks remain significant, with 42% of patients at the 8 mg/kg dose experiencing grade 3 or higher treatment-related adverse events, which could limit real-world use or affect regulatory review.
• ●The phase Ib trial is small (n=50) and ongoing, so efficacy and safety signals may shift with larger, more diverse populations in phase III, introducing uncertainty about generalisability.
• ●Regulatory and commercial success is not assured, as pivotal phase III data are still pending and the competitive landscape in relapsed ES-SCLC is evolving, with no clear standard of care in later lines.
• ●Capital intensity is high, as GSK has acquired global rights (excluding China, Hong Kong, Macau, and Taiwan) and is running multiple phase III trials, but no financial metrics or commercial forecasts are disclosed, making return on investment uncertain.

Bottom line

GSK’s Ris-Rez delivers encouraging phase Ib efficacy and safety data in relapsed extensive-stage small cell lung cancer, with a 61% response rate at the selected 8 mg/kg dose and a manageable but notable rate of severe adverse events. The program is ambitious, with more than 1,000 patients treated and multiple phase III trials underway, and has secured key global regulatory designations. Yet, the data are early, durability is unproven, and safety risks could impact ultimate adoption. No financial or commercial projections are provided, so investors cannot assess potential returns or market impact at this stage. The most important takeaway is that while Ris-Rez is a promising asset in a high-need indication, the path to regulatory approval and commercialisation remains long and uncertain, and pivotal phase III results will be the true inflection point.

Announcement summary

(LSE:GSK) GSK plc announced the first global data for risvutatug rezetecan (Ris-Rez), its investigational B7-H3-targeted antibody-drug conjugate (ADC), in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC). In the phase Ib dose-optimisation portion of the EMBOLD PanTumour-101 trial, Ris-Rez achieved a confirmed objective response rate (ORR) of 61% among evaluable patients at the 8 mg/kg dose (n=11/18; 95% CI: 35.7-82.7), compared with 32% at the 6 mg/kg dose (n=7/22; 95% CI: 13.9-54.9). The safety profile was manageable across both dose levels at a median follow-up of 100.5 days. Grade 3 or higher treatment-related adverse events (TRAEs) were observed in 42% of patients receiving 8 mg/kg and 15% of those receiving 6 mg/kg, with haematological events being the most common. The overall rate of interstitial lung disease (ILD) was low at 2% (1 out of 50 patients), and the case was moderate (grade 2). These results build on positive pivotal data in Chinese patients and support accelerated Ris-Rez development, including in the ongoing global phase III EMBOLD SCLC-301 study. The data will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. The analysis included 50 patients who had received a median of two prior therapies, with the study population including patients with prior topoisomerase-1 inhibitor or tarlatamab exposure, as well as those with brain or liver metastases. Enrolment in the phase Ib dose-optimisation portion was ongoing at data cut-off, and longer follow-up will be needed to further characterise the durability of response. More than 1,000 patients have received Ris-Rez as part of GSK’s global EMBOLD clinical trial programme, which includes phase III trials in late-line ES-SCLC and metastatic castration-resistant prostate cancer (mCRPC), with additional phase III trials planned in early-line SCLC and chemo-naïve mCRPC. GSK acquired exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez. Ris-Rez has received several global regulatory designations, including orphan drug designations in the US, Japan, and the EU for SCLC, Breakthrough Therapy Designation in the US, and Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC. In China, Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer. Approximately 70% of patients with SCLC are diagnosed with extensive-stage disease (ES-SCLC). Small cell lung cancer accounts for approximately 10-15% of all lung cancer diagnoses worldwide. Median overall survival for patients with ES-SCLC treated with current standard-of-care therapies is approximately 12 to 13 months. GSK is focused on developing differentiated medicines for cancers with poor outcomes, treatment resistance, limited options, or significant treatment burden.

Disagree with this article?